Register Login
Register to leave comments
  • News bot March 24, 2026, 8:23 p.m.

    📋 FENNEC PHARMACEUTICALS INC. (FENC) - Financial Results

    Filing Date: 2026-03-24

    Accepted: 2026-03-24 16:22:46

    Event Type: Financial Results

    Event Details:

    FENNEC PHARMACEUTICALS INC. (FENC) Reports the reporting period Financial Results FENNEC PHARMACEUTICALS INC. (FENC) announced its financial results for the period ending the reporting period. Key Financial Highlights:
    • Revenue: 1764
    • Net Income: Not disclosed
    • EPS: Not disclosed
    • Cash and equivalents: 36788
      • based treatment, demonstrating that the Company’s growth strategies are well aligned with market opportunities.​●Expanded Field Team to Accelerate Growth: In the fourth quarter, given the positive momentum Fennec observed over 2025, the Company made the strategic decision to further enhance its execution by increasing its customer facing team to achieve greater reach and frequency with its customers so the organization can ultimately help more cancer patients protect their hearing. ​●New Real
      • World Data in Adults with Head and Neck Cancer (HNC): In February 2026, Fennec announced it presented the first new data since the pivotal clinical program at the 2026 Multidisciplinary Head and Neck Cancers Symposium (MHNCS). Findings supporting the potential use of PEDMARK® in adults with head and neck cancers (HNC) were observed in a multi
      • institutional retrospective review of 15 adults with HNC. The data showed that PEDMARK® could be safely given ≥ six hours after cisplatin dosing and was easy to incorporate into the real

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2025 2024 Change ($) Change (%)
    Loss From Operations -934.00 -6.74K $5.81K +86.15%
    Other Expenseincome Interest Income 399.00 787.00 $-388.00 -49.30%
    Other Expenseincome Interest Expense -966.00 -2.08K $1.11K +53.56%
    Income Tax Net Loss -1.62K -10.10K $8.48K +83.97%
    Current Liabilities Accounts Payable 4.63K 4.63K $0.00 +0.00%
    Current Liabilities Accrued Liabilities 5.63K 5.63K $0.00 +0.00%
    Long Term Liabilities Other Long Term Liabilities 24.56K 24.56K $0.00 +0.00%
    Revenue 13.78K 7.92K $5.85K +73.84%
    Loss from Operations -3.02K -934.00 $-2.08K -222.91%
    Interest Income 228.00 399.00 $-171.00 -42.86%
    Interest Expense -308.00 -966.00 $658.00 +68.12%
    Net Loss -5.14K -1.62K $-3.52K -217.73%
    Accounts Payable 4.63K 4.63K $0.00 +0.00%
    Accrued Liabilities 5.63K 5.63K $0.00 +0.00%

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: FENNEC PHARMACEUTICALS INC.
    • Ticker Symbol: FENC

Search

News categories